亚甲基四氢叶酸还原酶基因多态性与乳腺癌新辅助化疗敏感性关系的研究探讨

季明华; 吴建中; 唐金海

doi:10.3969/j.issn.1672-2353.2012.01.001

亚甲基四氢叶酸还原酶基因多态性与乳腺癌新辅助化疗敏感性关系的研究探讨

1.
江苏省肿瘤医院放疗科,江苏南京,210009;
2.
江苏省肿瘤医院中心实验室,江苏南京,210009;
3.
江苏省肿瘤医院普外科,江苏南京,210009

详细信息

中图分类号: R737.9 R730.53
计量
- 文章访问数: 147
- HTML全文浏览量: 24
- PDF下载量: 11
出版历程
- 发布日期: 2012-04-26

Relationship between genetic polymorphisms of methylenetetrahydrofolate reductase and sensitivity of breast cancer to neoadjuvant chemotherapy

摘要

摘要: 目的研究叶酸代谢的关键酶亚甲基四氢叶酸还原酶(MTHFR)基因C677T、A1298C多态与乳腺癌患者对新辅助化疗敏感性的关系.方法收集经病理学或细胞学确诊的乳腺癌患者61例,均给予新辅助化疗.接受环磷酰胺、表阿霉素、5-氟尿嘧啶联合化疗方案(CAF)化疗34例,表阿霉素、紫杉醇联合化疗方案(AT方案)化疗27例.所有病例化疗前抽静脉血,提取白细胞DNA,用聚合酶链反应限制性片段长度多态性(PCR RFLP)技术检测MTHFR基因型.化疗后均测量肿块大小进行疗效评价,手术均行病理检查,观察化疗反应分级情况.结果 61例乳腺癌患者中,使用CAF方案和AT方案的临床有效率分别为61.5％、75.0％,差异无统计学意义；Ⅰ～Ⅲ级化疗反应率分别为55.9％、74.1％,差异无统计学意义.携带MTHFR C677T T/T基因型、C/T基因型、C/C基因型的乳腺癌患者化疗的临床有效率分别为83.3％、72.4％、42.9％,Ⅰ～Ⅲ级化疗反应率分别为83.3％、65.5％、35.7％.携带T/T基因型乳腺癌患者的临床有效率和Ⅰ～Ⅲ级化疗反应率均显著高于携带C/C基因型的患者,而与携带C/T基因型患者相比差异无统计学意义.携带MTHFR A1298C A/A基因型、A/C基因型、C/C基因型的乳腺癌患者化疗的临床有效率分别为70.5％、64.7％、0.0％,Ⅰ～Ⅲ级化疗反应率分别为70.5％、47.1％、0.0％.携带MTHFR A1298C A/A基因型患者的临床有效率和Ⅰ～Ⅲ级化疗反应率与A/C及C/C基因型患者之间差异均无统计学意义.结论 MTHFR C677T基因多态性的作用与乳腺癌新辅助化疗敏感性之间存在着一定的相关性,对预测乳腺癌新辅助化疗的疗效具有良好的临床应用前景.
- 乳腺癌 /
- 亚甲基四氢叶酸还原酶 /
- 新辅助化疗 /
- 转化医学

HTML全文

参考文献(11)

Goyette P, Sumner J S, Frosst P. Human methyenerahydrofolate reductase:isolation of cDNA, mapping and mutation identification [J]. Nature Genetics, 1994(4):551.

Satoh A, Toyota M, Itoh F. Epigenetic Inactivation of CHFR and Sensitivity to Microtubule Inhibitors in Gastric Cancer [J]. Cancer Research, 2003, (24):8606.

Narayan G, Arias-Pulido H, NandulaSV. Promoter Hypermethylation of FANCF-Disruption of Fanconi Anemia-BRCA Pathway in Cervical Cancer [J]. Cancer Research, 2004(9):2994.

Chekhun V F, Kulik G I, Yurchenko O V. Role of DNA hypomethylation in the development of the resistance to doxorubicin in human MCF-7 breast adenocarcinoma cells [J]. Cancer Letters, 2006(1):87.

高长明, 陆建伟, Takezaki Toshiro. 亚甲基四氢叶酸还原酶基因多态性与胃癌化疗的敏感性关系的研究 [J]. 中华流行病学杂志, 2004, (12):1054.doi: 10.3760/j.issn:0254-6450.2004.12.011.

Goyette P, Fosst P, Dasrid S R. Seven novel mutation in the MTHFR gene and genotype/phenotype correlation in severe methylenetetrahydrofolate reductase deficiency [J]. American Journal of Human Genetics, 1995(5):1052.

Frosst P, Blom H J, Milos R. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase [J]. Nature Genetics, 1995(1):111.

Stern L L, Mason J B, Selhub J. Genomic DNA hypomethylation, a characteristic of most cancers, is present in peripheral leukocytes of individuals who are homozygous for the C677T polymorphism in the methylenetetrahydrololate reductase gene [J]. Cancer Epidemiology Biomarkers and Prevention, 2000(8):849.

张天泽, 徐光炜. 肿瘤学(中册) [M]. 天津:天津科学技术出版社, 1996.1629.

Vander Put N M, Gabreels F, Stevens E M. A second common mutation in the methylenetetrahydrololate reductase gene:an additional risk factor for neural-tube defects [J]. American Journal of Human Genetics, 1998(2):1044.

Ruzzo A, Graziano F, Kaw akami. Pharmacogenetic profiling and clinical outcome of patients with advanced gastric cancer treated with palliative chemotherapy [J]. Journal of Clinical Oncology, 2006, (12):1883.

施引文献

资源附件(0)

计量

文章访问数: 147
HTML全文浏览量: 24
PDF下载量: 11
被引次数: 0

亚甲基四氢叶酸还原酶基因多态性与乳腺癌新辅助化疗敏感性关系的研究探讨

计量

出版历程

Relationship between genetic polymorphisms of methylenetetrahydrofolate reductase and sensitivity of breast cancer to neoadjuvant chemotherapy

计量

出版历程

目录